schliessen

Filtern

 

Bibliotheken

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects

Background Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examinati... Full description

Journal Title: The American heart journal 2011, Vol.161 (4), p.719-725
Main Author: Muntner, Paul, PhD
Other Authors: Mann, Devin, MD , Wildman, Rachel P, PhD , Shimbo, Daichi, MD , Fuster, Valentin, MD , Woodward, Mark, PhD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-8703
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3093765
title: Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
format: Article
creator:
  • Muntner, Paul, PhD
  • Mann, Devin, MD
  • Wildman, Rachel P, PhD
  • Shimbo, Daichi, MD
  • Fuster, Valentin, MD
  • Woodward, Mark, PhD
subjects:
  • Abridged Index Medicus
  • Adults
  • Atherosclerosis (general aspects, experimental research)
  • Biological and medical sciences
  • Blood and lymphatic vessels
  • Cardiology. Vascular system
  • Cardiovascular
  • Cardiovascular diseases
  • Cardiovascular Diseases - drug therapy
  • Cardiovascular Diseases - epidemiology
  • Cardiovascular Diseases - prevention & control
  • Complications and side effects
  • Drug Combinations
  • Drug therapy
  • Female
  • Humans
  • Incidence
  • Male
  • Medical sciences
  • Middle Aged
  • Risk Factors
  • Surveys and Questionnaires
ispartof: The American heart journal, 2011, Vol.161 (4), p.719-725
description: Background Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4186544
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3093765
sourceformatXML
sourcesystemPC
galeidA253635972
sourcerecordidA253635972
originalsourceidFETCH-LOGICAL-1638t-b76b7296968c90ac78c7c37f65165274527f9b4d5d8a0f5bf96f14461ce886373
addsrcrecordideNp9kl1v0zAUhiMEYmXwA7hBvgFu1mLHie2ANGma-JKGQBq7tlz7uHXmxJ2dVOq_x6FlbLuYoihx_LzHds5TFK8JXhBM2Id2odbtosTTuFxg0jwpZgQ3fM54VT0tZhjjci44pkfFi5TaPGSlYM-Lo5JUnDaczIqbXzG0oAcwyHUbpQcULNoEv9s479GYAKku9Ct0dYmUGf2QPqIfYJxWgwv9NH-CtIrGha1KevQqoujSNYpgRj0hJ0j1BiVnAIG1eaH0snhmlU_w6vA8Lq6-fP59_m1-8fPr9_OzizlhVAzzJWdLXjasYUI3WGkuNNeUW1YTVpe8yrdtlpWpjVDY1kvbMEuqihENQjDK6XFxuq-7GZcdGA39EJWXm-g6FXcyKCfvz_RuLVdhKyluKGd1LvD-UCCGmxHSIDuXNHiveghjkoKREnMiJnKxJ1fKg3S9DbmgzpeBzunQg3X5-1lZU0brhpc58O5OYA3KD-sU_Dj9sXQfJHtQx5BSBHu7f4Ll5IBsZXZATg5IUsrsQM68uXvw28S_pmfg7QHIPVPeRtVrl_5zFRY1qWjm-IPFtRv-Nj4fz_lHt_Bpn4Tc4K2DKJN20OtsTswOSBPco-nTB2ntXZ-d89ewg9SGMfbZHElkygF5OWk-WU5IfsOC0D-otfWw
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid861207185
display
typearticle
titleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
sourceAlma/SFX Local Collection
creatorMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
creatorcontribMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
descriptionBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2010.12.019
3PMID: 21473971
4CODEN: AHJOA2
languageeng
publisherNew York, NY: Elsevier Inc
subjectAbridged Index Medicus ; Adults ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Complications and side effects ; Drug Combinations ; Drug therapy ; Female ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Risk Factors ; Surveys and Questionnaires
ispartofThe American heart journal, 2011, Vol.161 (4), p.719-725
rights
0Mosby, Inc.
12011 Mosby, Inc.
22015 INIST-CNRS
3Copyright © 2011 Mosby, Inc. All rights reserved.
4COPYRIGHT 2011 Elsevier B.V.
52011 Mosby, Inc. All rights reserved. 2011
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1638t-b76b7296968c90ac78c7c37f65165274527f9b4d5d8a0f5bf96f14461ce886373
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24085143$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21473971$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
title
0Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
1The American heart journal
addtitleAm Heart J
descriptionBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
subject
0Abridged Index Medicus
1Adults
2Atherosclerosis (general aspects, experimental research)
3Biological and medical sciences
4Blood and lymphatic vessels
5Cardiology. Vascular system
6Cardiovascular
7Cardiovascular diseases
8Cardiovascular Diseases - drug therapy
9Cardiovascular Diseases - epidemiology
10Cardiovascular Diseases - prevention & control
11Complications and side effects
12Drug Combinations
13Drug therapy
14Female
15Humans
16Incidence
17Male
18Medical sciences
19Middle Aged
20Risk Factors
21Surveys and Questionnaires
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2011
recordtypearticle
recordideNp9kl1v0zAUhiMEYmXwA7hBvgFu1mLHie2ANGma-JKGQBq7tlz7uHXmxJ2dVOq_x6FlbLuYoihx_LzHds5TFK8JXhBM2Id2odbtosTTuFxg0jwpZgQ3fM54VT0tZhjjci44pkfFi5TaPGSlYM-Lo5JUnDaczIqbXzG0oAcwyHUbpQcULNoEv9s479GYAKku9Ct0dYmUGf2QPqIfYJxWgwv9NH-CtIrGha1KevQqoujSNYpgRj0hJ0j1BiVnAIG1eaH0snhmlU_w6vA8Lq6-fP59_m1-8fPr9_OzizlhVAzzJWdLXjasYUI3WGkuNNeUW1YTVpe8yrdtlpWpjVDY1kvbMEuqihENQjDK6XFxuq-7GZcdGA39EJWXm-g6FXcyKCfvz_RuLVdhKyluKGd1LvD-UCCGmxHSIDuXNHiveghjkoKREnMiJnKxJ1fKg3S9DbmgzpeBzunQg3X5-1lZU0brhpc58O5OYA3KD-sU_Dj9sXQfJHtQx5BSBHu7f4Ll5IBsZXZATg5IUsrsQM68uXvw28S_pmfg7QHIPVPeRtVrl_5zFRY1qWjm-IPFtRv-Nj4fz_lHt_Bpn4Tc4K2DKJN20OtsTswOSBPco-nTB2ntXZ-d89ewg9SGMfbZHElkygF5OWk-WU5IfsOC0D-otfWw
startdate2011
enddate2011
creator
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
general
0Elsevier Inc
1Mosby
2Elsevier B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
107X8
115PM
sort
creationdate2011
titleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
authorMuntner, Paul, PhD ; Mann, Devin, MD ; Wildman, Rachel P, PhD ; Shimbo, Daichi, MD ; Fuster, Valentin, MD ; Woodward, Mark, PhD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1638t-b76b7296968c90ac78c7c37f65165274527f9b4d5d8a0f5bf96f14461ce886373
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Abridged Index Medicus
1Adults
2Atherosclerosis (general aspects, experimental research)
3Biological and medical sciences
4Blood and lymphatic vessels
5Cardiology. Vascular system
6Cardiovascular
7Cardiovascular diseases
8Cardiovascular Diseases - drug therapy
9Cardiovascular Diseases - epidemiology
10Cardiovascular Diseases - prevention & control
11Complications and side effects
12Drug Combinations
13Drug therapy
14Female
15Humans
16Incidence
17Male
18Medical sciences
19Middle Aged
20Risk Factors
21Surveys and Questionnaires
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9MEDLINE - Academic
10PubMed Central (Full Participant titles)
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Muntner, Paul, PhD
1Mann, Devin, MD
2Wildman, Rachel P, PhD
3Shimbo, Daichi, MD
4Fuster, Valentin, MD
5Woodward, Mark, PhD
formatjournal
genrearticle
ristypeJOUR
atitleProjected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
jtitleThe American heart journal
addtitleAm Heart J
date2011
risdate2011
volume161
issue4
spage719
epage725
pages719-725
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractBackground Polypills, which include multiple medications for reducing cardiovascular disease (CVD) risk in a single pill, have been proposed for population-wide use. The number of US adults eligible for polypills and potential benefits are unknown. Methods The National Health and Nutrition Examination Survey 2003-2004 and 2007-2008 were analyzed to estimate treatment rates for medications proposed for inclusion in polypills (aspirin, statin, an angiotensin-converting enzyme [ACE] inhibitor, and a thiazide-type diuretic for those without and a β-blocker for those with a history of myocardial infarction) among US adults. The number of coronary heart disease (CHD) and stroke events potentially prevented through polypill use was projected by published meta-analyses and 3 large population-based cohort studies. Two polypill eligibility criteria were analyzed: (1) US adults ≥55 years and (2) US adults with a history of CVD. Results There are 67.6 million US adults ≥55 years and 15.4 million US adults with a history of CVD and, thus, eligible for polypills using the 2 outlined criteria. In 2007 to 2008, 37.3% of US adults ≥55 years and 57.0% of those with a history of CVD were taking statins. Use of other polypill medications was also low. Polypill use by US adults aged ≥55 years is projected to potentially prevent 3.2 million CHD events and 1.7 million strokes over 10 years. Among those with a history of CVD, the potential to prevent of 0.9 million CHD events and 0.5 million strokes is projected. Conclusions Polypills have the potential to lower CVD incidence substantially among US adults.
copNew York, NY
pubElsevier Inc
pmid21473971
doi10.1016/j.ahj.2010.12.019
oafree_for_read